|05/09/13||Kips Bay Medical Provides FDA Update and Reports First Quarter 2013 Results|
|MINNEAPOLIS--(BUSINESS WIRE)--May. 9, 2013--
Kips Bay Medical, Inc. (NASDAQ: KIPS) today provides an FDA update and
announces financial results for its first quarter ended March 30, 2013.
Enrollments continue at a modest pace in the Kips Bay eMESH I
clinical feasibility trial. As of May 1, 2013, the number of sites
actively recruiting patients, in Europe and the United States, has
increased to seven. An additional three ... |
|05/02/13||Kips Bay Medical Announces the First eSVS® Mesh Implant by the Mayo Clinic|
|MINNEAPOLIS--(BUSINESS WIRE)--May. 2, 2013--
Manny Villafaña, Chairman and CEO of Kips Bay Medical, Inc.
(NASDAQ:KIPS) announced that on April 30, 2013, the Mayo Clinic
performed its first implant of an eSVS® Mesh at its
Rochester, Minnesota facility. This implant was performed as part of the
Kips Bay Medical eMESH I clinical feasibility trial currently being
conducted for the U.S. FDA in a number of preeminent cardiac surgery
centers in both Euro... |
|04/26/13||Kips Bay Medical Announces Operating and Financial Results and Conference Call Date for First Quarter 2013|
|MINNEAPOLIS--(BUSINESS WIRE)--Apr. 26, 2013--
Manny Villafaña, Chairman and CEO of Kips Bay Medical Inc. (NASDAQ:KIPS)
announced today that Kips Bay will release operating and financial
results for the first quarter ended March 30, 2013 on Thursday, May 9,
2013 prior to market open and will hold a conference call to discuss
those results at 9:00 A.M. (Eastern Time).
The call can be accessed in the following ways:
In the I... |
|03/28/13||Kips Bay Medical Provides FDA Update & Reports Fourth Quarter and Full Year 2012 Results|
|MINNEAPOLIS--(BUSINESS WIRE)--Mar. 28, 2013--
Kips Bay Medical, Inc. (NASDAQ: KIPS) along with Manny Villafaña, its
Founder, Chairman and CEO, today provided an update on its progress with
the U.S. FDA and announced financial results for fourth quarter and year
ended December 31, 2012.
Receipt of IDE approval with conditions from the U.S. FDA.
U.S. FDA approve... |